Taysha Gene Therapies, Inc.TSHANASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -43.90% | -32.51% | +78.60% | -100.00% | +171.27% |
| Gross Profit Growth | -43.90% | -32.51% | +78.60% | -116.00% | +13.85% |
| EBITDA Growth | -137.81% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -139.35% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -135.90% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -135.90% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +9.62% | +16.46% | +27.99% | +31.92% | +56.00% |
| Weighted Average Shares Diluted Growth | +9.62% | +16.46% | +27.99% | +31.92% | +56.00% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -7.16% | -9.57% | +66.34% | +75.65% | +114.09% |
| Book Value per Share Growth | -12.93% | -12.20% | +78.50% | +86.95% | +121.31% |
| Debt Growth | +3.39% | +1.07% | +3.25% | +10.47% | -71.24% |
| R&D Expense Growth | +20.84% | -24.65% | +33.62% | +70.34% | +64.69% |
| SG&A Expenses Growth | -1.34% | +15.16% | +17.17% | +4.77% | +33.25% |